Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

International Big Pharma Continues China Investment

publication date: Nov 18, 2008

Worldwide, big pharma may be retrenching, but it continues to invest in China. Because China’s drug market is young and growing, the country represents opportunity for these industry veterans, an opportunity that is made more attractive by their difficulties elsewhere. It’s not surprising, therefore, that several big pharmas have expressed their intention to enlarge their presence in China. Novartis, Novo Nordisk, GlaxoSmithKline, Bayer Schering and Bristol-Myers Squibb have each been in China biopharma news in recent days. More details...

Stock Symbols: (NYSE: NVS) (NYSE: NVO) (NYSE: GSK) (NYSE: BMY)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here